Date:7/30/2012

ments regarding: the expansion of our installed base; distribution for our instruments; purchases of our consumable products; the development progress and market acceptance of our assay products, including NeoPlex4 and NeoPlex System and products developed and manufactured by Luminex Madison and Luminex Molecular Diagnostics; anticipated FDA clearance of our products, including Gastrointestinal Pathogen Panel, NeoPlex4 and NeoPlex System;status of integration of Luminex Madison; the acquisition of GenturaDx; the addition of Luminex to the S&P Small Cap 600 GICS; Luminex's long-term strategic plan and acquisition strategy; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2012 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementat
'/>"/>

SOURCE Luminex Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
2. Luminex Corporation Announces Agreement to Acquire GenturaDx
3. Luminex Corporation Reports First Quarter 2012 Results
4. Unilife Corporation Announces Financial Results For Fiscal Year 2012 Fourth Quarter
5. Gentris Corporation Announces Collaboration to Study Blood Stability
6. Unilife Corporation to Announce Financial Results for Fiscal 2012 Fourth Quarter and Year End on Monday, July 30, 2012
7. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
8. Celladon Corporation Receives Patent from United States Patent and Trademark Office
9. Gentris Corporation Launches New Pharmacogenomics Services
10. BioElectronics Corporation Announces Initiative for UK and German Markets
11. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.